Latest Gabather News & Updates

See the latest news and media coverage for Gabather. We track all announcements, press releases, and industry mentions in real time, all in one place.

Gabather

Pharmaceutical company developing CNS therapeutics

gabather.com

Headquarters: Södertälje, Sweden
Founded year: 2014
Company type: Public company
Number of employees: 4–10

Last updated Today

Latest news about Gabather

In short: Gabather launched a Phase II clinical study of its drug candidate GT-002 for schizophrenia and secured new patents for psychiatric treatments.

Company announcements

May 20 Gabather

Gabather initiates phase II study of GT-002 for schizophrenia

The study targets cognitive symptoms with no approved treatments, aiming for a licensing deal in 2026.

May 11 Gabather

Gabather launches Phase II TOTEMS study for GT-002

The study evaluates GT-002 in schizophrenia patients, marking a key milestone after years of development.

25 November 2025 Gabather

Gabather announces GT-002 study results

Presents acute effects on psychophysiological and cognitive measures. Dated 25 November 2025. Download presentation available.

13 May 2025 Gabather

Gabather begins GT002 capsule production

CEO announces milestone at partner facility in Spain for upcoming clinical trial. Capsules finalize this week, followed by packaging, labeling, and shipment to Denmark.

Media coverage

May 7 Life Science Sweden

Gabather in collaboration with Danish hospital - starts schizophrenia study

The Södertälje company Gabather will for the first time test effect on cognition in schizophrenia in patients with its most advanced drug candidate.

March 18 BioStock

Gabather carries out a directed new share issue of SEK 4,2 million - Biostock

Gabather is conducting a directed new share issue of approximately SEK 4,2 million with the aim of strengthening the balance sheet and current working capital...

12 February 2024 Seeking Alpha

Gabather Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct a Clinical Phase II Study with GT-002

STOCKHOLM, April 10, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) announces that the Company has signed a Collaborative Agreement with the...

12 February 2024 Seeking Alpha

Gabather reports initial positive results from the EEG/fMRI target engagement study

STOCKHOLM, March 7, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports initial positive results from the EEG/fMRI target engagement study...

Never miss news about Gabather

Track Gabather and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Gabather competitors & trending companies

Browse news for competitors to Gabather and other trending companies.